aTYR PHARMA INC
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10.4M | $0 | $10.5M | $422.0K |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M | $17.3M | $14.0M |
| SG&A Expense | $17.6M | $13.8M | $13.0M | $14.0M | $10.8M | $9.1M | $9.4M |
| Operating Income | $-77.6M | $-67.9M | $-54.9M | $-46.4M | $-34.0M | $-15.9M | $-23.0M |
| Operating Margin | -40,856.3% | -28,899.6% | -15,557.8% | -446.8% | — | -152.2% | -5,445.0% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-74.1M | $-64.0M | $-50.4M | $-45.3M | $-33.8M | $-16.2M | $-23.8M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-74.1M | $-64.0M | $-50.4M | $-45.3M | $-33.8M | $-16.2M | $-16.2M |
| Net Margin | -39,009.5% | -27,243.8% | -14,274.5% | -436.5% | — | -155.2% | -3,844.5% |
| EPS (Basic) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-0.89 | $-3.52 |
| EPS (Diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-0.89 | $-3.52 |
| Shares Outstanding (Basic) | 93.0M | 74.3M | 53.6M | 28.4M | 19.1M | 18.3M | 7.8M |
| Shares Outstanding (Diluted) | 93.0M | 74.3M | 53.6M | 28.4M | 19.1M | 18.3M | 7.8M |
| Dividends Per Share | — | — | — | — | — | — | — |